Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
FDA-approved for type 2 diabetes (May 2022) Dual GIP/GLP-1 co-agonist first-in-class incretin A1C reductions up to ~2.4% in SURPASS pivotal trials Insurance billing or LillyDirect cash-pay options shipping doctors doctor 24/7 Same price at every dose
But with more patients without diabetes now taking an interest in medications like Ozempicand research suggesting that people can gain weight after they stop using GLP-1sbehavior and lifestyle changes are key
With the latter, youre simply getting a shot of something special, like B12
Research on orforglipron Clinical studies suggest that orforglipron can significantly improve both weight loss and blood sugar control in adults with obesity or type 2 diabetes
